NEW Zealand-based global medical device company Fisher & Paykel Healthcare has reported to the ASX that costs are forecast to increase under the new US tariff regime, which resulted in a 7.4% drop in share price.
The US announced a 25% tariff would be imposed on products imported from Mexico and Canada, and a 10% tariff on products from China.
F&P Healthcare, which makes in-home CPAP devices for managing obstructive sleep apnoea and humidifiers for chronic respiratory care, currently manufactures about 45% of its volume in Mexico, and the US accounts for 43% of the company's revenue.
However, the company said it doesn't expect a material impact on profits for the 2025 financial year.
The above article was sent to subscribers in Pharmacy Daily's issue from 04 Feb 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Feb 25